Cite
HARVARD Citation
Lee, W. et al. (2022). Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade. Journal for immunotherapy of cancer. 10 (6), p. . [Online].